The Union Ministry of Health and Family Welfare has issued a draft amendment to the Drugs Rules, 1945, introducing a key regulatory distinction under Schedule K between liquid antiseptics meant for household use and those intended for hospital or institutional use. The draft amendment has been notified as G.S.R. 759(E) in the Gazette dated 16 October 2025, and is open for public comments and stakeholder input.

Split of Liquid Antiseptics into Two Categories

  1. Liquid Antiseptics for Household Use (Entry 39)

    Household antiseptics will continue to be exempt from Chapter IV licensing requirements, subject to stricter conditions:

    • Production must be carried out only by licensed manufacturers.
    • Formulations cannot include substances listed under Schedules G, H, H1, or X.
    • Products must be sold in their original, unopened containers.
    • Every level of packaging must clearly display the label “For household use.

  2. Liquid Antiseptics for Hospital and Other Non-Household Use (Entry 39A)

    Hospital-grade antiseptics will no longer be exempt under Chapter IV and must be sold under a Form 20 or Form 20A sale licence. The conditions include:

    • Manufacturing restricted to licensed entities.
    • Exclusion of Schedules G, H, H1, and X remains applicable.
    • Sale must be in original containers only.
    • Purchases allowed only from licensed wholesalers or manufacturers.
    • Labels must clearly state “For hospital and other than household use.

Significance and Industry Impact

Consumers will continue to have easy access to household antiseptics without additional retail licensing burdens. Hospitals, clinics and professional institutions will now be required to procure hospital-grade antiseptics through authorized sale licenses, ensuring better traceability, safety and compliance. Manufacturers and distributors must revise labeling, packaging and supply-chain practices to reflect the new classifications and meet updated regulatory standards.

Next Steps

The amendment signals an important step in strengthening India’s pharmaceutical regulatory framework. Final approval is anticipated later this year. Industry stakeholders are advised to monitor further notifications and actively participate in the consultation process to align their operations with the upcoming regulatory framework.